ERBB2 and breast cancer: In HER2-positive human breast cancer and gastric cancer cells, trastuzumab resistance is induced by high expression of MUC4 through the NF-κB pathway to reduce the effectiveness of ADCC (antibody-dependent cell-mediated cytotoxicity) in breast cancer cells and then induce drug resistance.